This Phase III study is evaluating the effectiveness of tafamidis as a treatment for transthyretin cardiomyopathy.
This trial is treating patients with Transthyretin Amyloid Cardiomyopathy.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)
This trial has one experimental arm. All participants will receive 61mg of tafamidis if available, and if not, 90mg of tafamidis megulmine. This will be administered orally via soft gel capsules once a day for 60 months.
Recruiting Hospitals Read More